Cefoxitin
- Generic Name
- Cefoxitin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C16H17N3O7S2
- CAS Number
- 35607-66-0
- Unique Ingredient Identifier
- 6OEV9DX57Y
- Background
Cefoxitin is a semi-synthetic, broad-spectrum cepha antibiotic for intravenous administration. It is derived from cephamycin C, which is produced by Streptomyces lactamdurans.
- Indication
For the treatment of serious infections caused by susceptible strains microorganisms.
- Associated Conditions
- Abscess, Intra-Abdominal, Animal bite, Bacterial Infections, Bacterial Urinary Tract Infections, Bone and Joint Infections, Endometritis, Flu caused by Influenza, Gynecological Infection, Intraabdominal Infections, Lower respiratory tract infection bacterial, Lung Abscess, Pelvic Inflammatory Disease (PID), Pelvic cellulitis, Peritonitis, Pneumonia, Septicemia, Skin and Subcutaneous Tissue Bacterial Infections
- Associated Therapies
- Antibiotic pre-surgical prophylaxis
Finding the Optimal Regimen for Mycobacterium Abscessus Treatment
- Conditions
- Interventions
- First Posted Date
- 2020-03-17
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- The University of Queensland
- Target Recruit Count
- 300
- Registration Number
- NCT04310930
- Locations
- 🇦🇺
St George Hospital, Kogarah, New South Wales, Australia
🇦🇺Austin Hospital, Heidelberg, Victoria, Australia
🇦🇺Royal Melbourne Hospital, Parkville, Victoria, Australia
Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy?
- Conditions
- Interventions
- First Posted Date
- 2017-09-01
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 962
- Registration Number
- NCT03269994
- Locations
- 🇺🇸
Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Hackensack Meridian Health / Hackensack University Medical Center Cancer Center, Hackensack, New Jersey, United States
Immediate Versus Delayed Induction in Term-PROM Using or Not Antibiotic Prophylaxis
- Conditions
- Interventions
- First Posted Date
- 2016-12-07
- Last Posted Date
- 2016-12-13
- Lead Sponsor
- Hospital de Santa Maria, Portugal
- Target Recruit Count
- 568
- Registration Number
- NCT02985086
- Locations
- 🇵🇹
Hospital de Santa Maria, CHLN, EPE, Lisbon, Portugal
🇵🇹Hospital Garcia de Orta, EPE, Almada, Portugal
Study of Repeated Cefoxitin Administration in Major Abdominal Surgery Using a Microdialysis Technique
- Conditions
- First Posted Date
- 2016-03-09
- Last Posted Date
- 2017-06-12
- Lead Sponsor
- Poitiers University Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT02703857
- Locations
- 🇫🇷
Centre Hospitalier de Poitiers, Poitiers, France
Evaluation of the Non-inferiority of Cefoxitin Versus Imipenem/Cilastatin in the Treatment of Urinary Tract Infections Caused by ESBL-producing Escherichia Coli
- First Posted Date
- 2015-06-18
- Last Posted Date
- 2017-08-11
- Lead Sponsor
- Central Hospital, Nancy, France
- Target Recruit Count
- 6
- Registration Number
- NCT02474706
- Locations
- 🇫🇷
CHRU Nancy, Nancy, France
Efficacy and Pharmacokinetic/Pharmacodynamic Parameters of Cefoxitin in Women With Acute Pyelonephritis Without Severity Symptoms Due to Extended-spectrum β-lactamase Producing Escherichia Coli
- Conditions
- Interventions
- First Posted Date
- 2013-03-29
- Last Posted Date
- 2018-01-12
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 9
- Registration Number
- NCT01820793
- Locations
- 🇫🇷
Agnès LEFORT, Clichy, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.